The Histamine Pathway is a Target to Treat Hepatic Experimental Erythropoietic ProtoporphyriaSummary

Background & Aims: Erythropoietic protoporphyria (EPP) is caused by mutations in ferrochelatase, which inserts iron into protoporphyrin-IX (PP-IX) to generate heme. EPP is characterized by PP-IX accumulation, skin photosensitivity, cholestasis, and end-stage liver disease. Despite available drug...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Ning Kuo, Pei Li, Juliana Bragazzi Cunha, Lu Chen, Jordan A. Shavit, M. Bishr Omary
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-01-01
Serija:	Cellular and Molecular Gastroenterology and Hepatology
Teme:	Anti-H1 Histamine Blocker Anti-H2 Histamine Blocker Ferrochelatase Porphyria-related Liver Disease
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2352345X25000049
Oznake:	Označite Brez oznak, prvi označite!